Trial Profile

A Comparative Randomized Double-Blind Study of Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac in Adult Study Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hepatitis B vaccine recombinant (Primary)
Indications Hepatitis B
Focus Pharmacodynamics
Sponsors VBI Vaccines

Most Recent Events

26 Jun 2021 Results assessing speed to seroprotection, immunogenicity and safety of prophylactic HBV vaccine from five clinical trials: PROTECT, CONSTANT, SG-005-05, 38-13-040 and SciB018 presented at The International Liver Congress 2021
29 Oct 2020 Primary endpoint (Seroconversion rate) has been met as per results published in the Clinical Infectious Diseases.
29 Oct 2020 Results published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com